Bluebird bio lays off 25% of workforce as gene therapy pioneer struggles to stay afloat
After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a restructuring that will reduce the size of its workforce by about 25%. | After bluebird bio acknowledged troubles keeping its business operational,
In a report released on September 24, Mani Foroohar from Leerink Partners maintained a Hold rating on Bluebird Bio (BLUE – Research ...
(Nasdaq: BLUE) today announced that it has completed the filing of its Form 10-Q for the quarter ended June 30 ...
Gene therapy for sickle cell disease remains a tough business model — and may never work, @adamfeuerstein writes.
Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This ...
SOMERVILLE, Mass. (AP) — SOMERVILLE, Mass. (AP) — Bluebird Bio Inc. (BLUE) on Friday reported a loss of $81.4 million in its second quarter. The Somerville, Massachusetts-based company said it had a ...
On Thursday, bluebird bio Inc (BLUE) stock saw a modest uptick, ending the day at $0.5 which represents a slight increase of $0.02 or 4.17% from the prior close of $0.48. The stock opened at $0.51 and ...
Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company’s cost structure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback